Sirtuin1 in COVID19 Patients

NCT04907916 | Unknown

• 1 other identifier: SIRTUIN1 in COVID19
• Study Type: observational
• Target: 130
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.Evaluate serum level of NAD,Sirtuin1,ADAM17 andPARP1 in covid19 patients
2. 2.Investigate the correlation between measured biomarkers and each other
3. 3.Investigate the correlation between measured biomarkers and each other and their correlation with covid19 severity and outcome which may help in the therapy and prevention of disease complication(cytokine storm)

Conditions

Covid19

Outcome Measures

Primary Outcomes (1)

• Sirtuin1 in COVID19

  The NAD dependent deacetylase activity of Sirtuin1 in COVID19

  1 year

Interventions

SIRTUIN1 OTHER

The NAD dependent deacetylase activity of Sirtuin1

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

COVID19 patient with clinical mainfastion with x.ray finding and positive PCR

You may qualify if:

• Patient adult age 18years and over(higher incidence) presented to Assiut University Hospital from 1december2020 to 30march.2021(winter2021-second wave)
• Suspected of covid19 beacuse of the presence of symptoms suggestive of pneumonia (fever\>38) and at least one of the following symptoms ;cough, dyspnea, tachpnea or hypoxia
• having undergone RT-PCR (confirmed positive PCR)
• Chest CT within 5 days of initial PCR

You may not qualify if:

• Cases less than 18 years old
• Cases express a dissent from the use of their data in the syudy
• Cancer patients (affect result of study as they have disrubted level of these biomarker)

Sponsors & Collaborators

• Assiut University: lead

Related Publications (4)

• Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, Porzio O, Mauriello A, Solini A, Ippoliti A, Lauro R, Folli F, Federici M. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes. 2009 Oct;58(10):2396-401. doi: 10.2337/db09-0280. Epub 2009 Jul 6.

  PMID: 19581416 BACKGROUND

• Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA, Jacobi A, Li K, Li S, Shan H. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020 Apr;295(1):202-207. doi: 10.1148/radiol.2020200230. Epub 2020 Feb 4.

  PMID: 32017661 BACKGROUND

• Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 2013 Oct 1;27(19):2072-85. doi: 10.1101/gad.227439.113.

  PMID: 24115767 BACKGROUND

• Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20. No abstract available.

  PMID: 32362390 BACKGROUND

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Hayam helmy mohamed, master degree

CONTACT

01097635337; hayamhelmy94@gmail.com

ragaa hamdy mohamed, professor

CONTACT

01063492008; ragaa-2002@yahoo.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: May 28, 2021
• First Posted: June 1, 2021
• Study Start: June 1, 2021
• Primary Completion: August 1, 2022
• Study Completion: January 1, 2023
• Last Updated: June 1, 2021

Record last verified: 2021-01